Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

A He; T Spelman; V Jokubaitis; E Havrdova; D Horakova; M Trojano; A Lugaresi; G Izquierdo; P Grammond; P Duquette; M Girard; E Pucci; G Iuliano; R Alroughani; C Oreja-Guevara; R Fernandez-Bolaños; F Grand'Maison; P Sola; D Spitaleri; F Granella; M Terzi; J Lechner-Scott; V Van Pesch; R Hupperts; JL Sánchez-Menoyo; S Hodgkinson; C Rozsa; F Verheul; H Butzkueven; T Kalincik; G Giuliani; E Cartechini; ME Rio; C Zwanikken; S Flechter; K Kasa; MP Amato; V Shaygannejad; R Bergamaschi; M Slee; C Boz; F Moore; M Barnett; S Vucic; P McCombe; JA Cabrera-Gomez; T Petersen; C Ramo; E Roullet; L Den Braber-Moerland; D Paolicelli; P Iaffaldano; V Direnzo; M D'Onghia; I Piroska; T Erdelyi; A Iljicsov; K Kovacs; A Sas; O Skibina; J Haartsen; E van Munster; M Fiol; J Correale; C Ysrraelit; J Herbert; I Kister; CA Sirbu; C Shaw; S Vetere; T Petkovska-Boskova; B Singhal; EA Bacile; WO Arruda; E Roger; P Despault; M Marriott; A Van der Walt; J King; J Byron; L Morgan; E Hinson; G De Luca; V Di Tommaso; D Travaglini; E Pietrolongo; M di Ioia; D Farina; L Mancinelli; JI Rojas; L Patrucco; D Williams; L Dark; A Savino; J Chapman; E Cristiano; ML Saladino; N Deri; O Gray; S Hughes

Journal article

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

A He, T Spelman, V Jokubaitis, E Havrdova, D Horakova, M Trojano, A Lugaresi, G Izquierdo, P Grammond, P Duquette, M Girard, E Pucci, G Iuliano, R Alroughani, C Oreja-Guevara, R Fernandez-Bolaños, F Grand'Maison, P Sola, D Spitaleri, F Granella Show all

JAMA Neurology | AMER MEDICAL ASSOC | Published : 2015

DOI: 10.1001/jamaneurol.2014.4147

Abstract

IMPORTANCE: After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicians advocate therapy switch, but the relative effectiveness of different switch decisions is often uncertain. OBJECTIVE: To compare the effect of the oral immunomodulator fingolimod with that of all injectable immunomodulators (interferons or glatiramer acetate) on relapse rate, disability, and treatment persistence in patients with activeMS. DESIGN, SETTING, AND PARTICIPANTS: Matched retrospective analysis of data collected prospectively from MSBase, an international, observational cohort study. The MSBase cohort represents a population of patients with MS monitor..

View full abstract

University of Melbourne Researchers

Timothy Spelman Author

Tomas Kalincik Author

Melanie Bahlo Author

Related Projects (5)

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

SELECTING OPTIMAL TREATMENT FOR PATIENTS WITH MULTIPLE SCLEROSIS

Multiple sclerosis is the most common cause of neurological disability among young people. With the increasing choice of therapies, the goal..

CENTRE FOR TRANSLATIONAL NEUROSCIENCE: A MODULAR PLATFORM FOR TRANSLATING DISCOVERY INTO HEALTH OUTCOMES

Clinical Centre of Research Excellence in Translational Neuroscience will provide people, pathways and resources to create a novel platform ..

TREATING PROGRESSIVE MULTIPLE SCLEROSIS

While there are numerous therapies for relapsing-remitting multiple sclerosis (MS), therapy for progressive MS remains elusive. This project..

Grants

Funding Acknowledgements

This investigator-initiated analysis was financially supported by Novartis Pharma, Multiple Sclerosis Research Australia (fellowship 11-054), National Health and Medical Research Council (fellowships 628856 and 1071124, grant 1032484, and Centre For Research Excellence grant 1001216), and MSBase Foundation (a not-for-profit organization that receives support from Bayer Schering, Biogen Idec, Merck Serono, Novartis Pharma, and Sanofi).